Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation
- 1 May 2013
- journal article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 168 (5), 675-681
- https://doi.org/10.1530/eje-12-1029
Abstract
Objective: Alterations in microRNA (miRNA) expression have been described in thyroid tumors, suggesting a role for miRNAs in thyroid carcinogenesis. BRAFV600E is the most frequently identified genetic alteration in papillary thyroid carcinoma (PTC). We investigated the link between BRAFV600E status and the expression of miRNAs in PTC and analyzed the associations of these factors with clinicopathological characteristics.Design and methods: Prospective study of patients who underwent thyroid surgery between October 8, 2008 and November 1, 2010. BRAFV600E status was determined by mutant allele-specific amplification PCR and direct sequencing of exon 15 of the BRAF gene in 69 PTC tissues and 69 respective paracancerous normal thyroid tissues. Initially, miRNA expression was analyzed in 12 PTC tissues and three associated paracancerous tissues using a miRNA microarray. miRNAs differentially expressed between BRAFV600E-positive and -negative PTC tissues were then validated by real-time quantitative PCR on 69 PTC tissues and 69 paracancerous tissues. We also explored the associations between BRAFV600E status or differential miRNA expression and clinicopathological characteristics.Results: The mutation rate of BRAFV600E in PTC was 47.8%. Twelve miRNAs were upregulated and six were downregulated in PTC tissues, among which miR-15a, 15a*, 34a*, 34b*, 551b, 873, 876-3p, and 1274a were first identified. miR-21* and 203 were significantly dysregulated (PBRAFV600E. Additionally, there were significant associations (PBRAFV600E and a higher tumor–node–metastasis staging (III/IV), and between miR-21* over-expression and lymph node metastasis.Conclusions: We identified two miRNAs that are differentially expressed in PTC tissues with BRAFV600E and revealed their associations with clinicopathological features. These findings may lead to the development of a potential diagnostic biomarker or prognostic indicator of PTC.Keywords
This publication has 38 references indexed in Scilit:
- BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial TreatmentMedicine, 2012
- BRAF V600E Mutation in Papillary Thyroid Carcinoma: Significant Association with Node Metastases and Extra Thyroidal InvasionEndocrine Pathology, 2011
- B-RafV600Eand thrombospondin-1 promote thyroid cancer progressionProceedings of the National Academy of Sciences of the United States of America, 2010
- BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical ImplicationsEndocrine Reviews, 2007
- No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in TaiwanClinical Endocrinology, 2005
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean PopulationYonsei Medical Journal, 2004
- Clinical Implication of Hot SpotBRAFMutation, V599E, in Papillary Thyroid CancersJournal of Clinical Endocrinology & Metabolism, 2003
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerAmerican Journal Of Medicine, 1994
- Prognostic Implications of the Tall Cell Variant of Papillary Thyroid CarcinomaThe American Journal of Surgical Pathology, 1988